Chinook Therapeutics Inc (NASDAQ:KDNY)
| 19.48 Delayed Data As of Sep 29 |  -0.27 / -1.37%Today’s Change | 10.48 Today|||52-Week Range 23.86 | +19.44% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.2B |
Company Description
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.
Contact Information
Chinook Therapeutics, Inc. 400 Fairview Avenue North Seattle Washington 98109 |
Employees
Shareholders
| Other institutional | 47.43% |
| Mutual fund holders | 17.91% |
| Individual stakeholders | 16.28% |
Top Executives
| Eric L. Dobmeier | Chairman, President & Chief Executive Officer |
| Tom Frohlich | Chief Operating Officer |
| Eric Hands Claude Bjerkholt | Chief Financial Officer |
| Andrew King | Chief Scientific Officer |
| Kirk D. Schumacher | Senior Vice President & General Counsel |
